On February 24, Heilongjiang Zbd Pharmaceutical Co.Ltd(603567) (603567, SH) issued an announcement to terminate the implementation of the restricted stock incentive plan in 2022. It is worth noting that Heilongjiang Zbd Pharmaceutical Co.Ltd(603567) the incentive plan has only about 18 days from its release to its termination.
On February 6, Heilongjiang Zbd Pharmaceutical Co.Ltd(603567) issued the 2022 restricted stock incentive plan (Draft), which plans to grant 1.5 million shares to the incentive object at the price of 7.37 yuan / share, accounting for 0.159% of the total share capital of the company on the date of the plan announcement. The total number of incentive objects is 51, including 5 company executives, including general manager Chen Hai, director and deputy general manager Yan Jiujiang, deputy general manager Guo Yidong, financial director Wang Lei and Board Secretary Zhang Haiying. The other 46 incentive objects are core business or technical backbone personnel.
The assessment year of the equity incentive plan is three fiscal years from 2022 to 2024, Heilongjiang Zbd Pharmaceutical Co.Ltd(603567) select the index reflecting the profitability of the enterprise “sales revenue of oral preparation products”, the index reflecting the operation ability of the enterprise “turnover rate of accounts receivable” and the index reflecting the long-term development potential “the proportion of total R & D expenditure to operating revenue” as the performance assessment index, It is stipulated that the proportion of total R & D expenditure in operating revenue shall not be less than 5%; Based on the audited financial data of 2021, the annual growth rate of sales revenue of oral preparation products shall not be less than 40%; In addition, in the three years from 2022 to 2024, based on the audited financial data of 2021, the growth rate of accounts receivable turnover rate shall not be less than 3%, 4% and 5% respectively.
Heilongjiang Zbd Pharmaceutical Co.Ltd(603567) it was originally planned to consider the 2022 restricted stock incentive plan (Draft) and its summary at the first extraordinary general meeting of 2022 on February 22. The meeting was postponed to March 2 and cancelled today.
For the reasons for the termination of the equity incentive plan, Heilongjiang Zbd Pharmaceutical Co.Ltd(603567) said that considering that the positions of some incentive objects in the incentive plan have been adjusted, in order to better achieve the expected incentive purpose, the scope of incentive objects needs to be further expanded and optimized. Considering the incentive effect of the incentive plan and the limitation of the disclosure window period of the annual report, the board of directors decided to terminate.
